6564 Share Price Performance
NT$21.10
-11.85 (-35.96%)
Price NT$21.10
Share PriceNT$21.10
Enimmune corporation Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
6564 Community Narratives
There are no narratives available yet.
Recent 6564 News & Updates
Enimmune corporation Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -2.28
- Gross Margin
- 33.56%
- Net Profit Margin
- -390.08%
- Debt/Equity Ratio
- 70.4%
Enimmune corporation Competitors
Snowflake Analysis
About 6564
- Founded
- 2014
- Employees
- n/a
- CEO
- WebsiteView website
Enimmune corporation operates as a biopharmaceutical Research and development, and marketing company in Taiwan. Its products include Tuberculin PPD RT23 SSI, an approved drug for tuberculin test to determine whether the patient is infected with tuberculosis. The company is also involved in the development of vaccines to prevent various infectious diseases, such as enterovirus, pneumonia, norovirus, dengue fever virus, Middle East respiratory syndrome coronavirus, etc. Enimmune corporation was founded in 2014 and is based in Taichung City, Taiwan.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Taiwanese Market Performance
- 7 Days: 3.8%
- 3 Months: 18.7%
- 1 Year: 17.6%
- Year to Date: 17.4%
The market has climbed 3.8% in the last 7 days, lead by the Information Technology sector with a gain of 5.5%. On the other hand, with a decline of 3.9%, the Healthcare sector is lagging behind. The market is up 18% over the last 12 months. Looking forward, earnings are forecast to grow by 18% annually. Market details ›